TransMedics Group, Inc. (TMDX)
Market Cap | 1.86B |
Revenue (ttm) | 151.08M |
Net Income (ttm) | -17.78M |
Shares Out | 32.63M |
EPS (ttm) | -0.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 454,097 |
Open | 55.21 |
Previous Close | 54.87 |
Day's Range | 55.18 - 57.16 |
52-Week Range | 38.86 - 99.63 |
Beta | 1.46 |
Analysts | Buy |
Price Target | 89.60 (+57.44%) |
Earnings Date | Nov 2, 2023 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for dou... [Read more]
Financial Performance
In 2022, TMDX's revenue was $93.46 million, an increase of 208.83% compared to the previous year's $30.26 million. Losses were -$36.23 million, -18.06% less than in 2021.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $89.6, which is an increase of 57.44% from the latest price.
News

TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
ANDOVER, Mass. , Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics Completes Acquisition of Summit Aviation
ANDOVER, Mass. , Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Aug. 7, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

TransMedics Reports Second Quarter 2023 Financial Results
ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

Bridge to Life Divests Certain Assets to TransMedics
NORTHBROOK, Ill. , Aug. 2, 2023 /PRNewswire/ -- Bridge to Life Ltd.

TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life
ANDOVER, Mass. , Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

TransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation
Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S. ANDOVER, Mass. , Aug. 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: T...

TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary
ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference
ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023
ANDOVER, Mass. , July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

TransMedics Reports First Quarter 2023 Financial Results
ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

TransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report
ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today anno...

TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results
ANDOVER, Mass. , Feb. 22, 2023 /PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
ANDOVER, Mass. , Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations
ANDOVER, Mass. , Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass. , Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics Reports Third Quarter 2022 Financial Results
Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $ 80 million to $85 million ANDOVER, Mass. , Nov. ...

TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022
ANDOVER, Mass. , Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

CIBC Innovation Banking Provides $60 Million Debt Financing to TransMedics Group Inc.
BOSTON--(BUSINESS WIRE)--CIBC Innovation Banking is pleased to announce a new debt financing for Massachusetts-based TransMedics Group, Inc. ("TransMedics"), a market leading medical technology compan...

TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

TransMedics Announces Upsize and Pricing of Public Offering of Common Stock
ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...